(Q64354889)
Statements
A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis (English)
0 references
June 2014
0 references
May 2017
0 references
0
0 references
18 year
0 references
50 year
0 references